These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 625789)

  • 1. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
    Campbell EW; Neff S; Bowdler AJ
    Transfusion; 1978; 18(1):94-7. PubMed ID: 625789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated intravascular coagulation after factor IX complex resolved using purified factor IX concentrate.
    Hadley T; Djulbegovic B
    Ann Intern Med; 1991 Oct; 115(8):621-2. PubMed ID: 1892334
    [No Abstract]   [Full Text] [Related]  

  • 4. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery.
    Conlan MG; Hoots WK
    Am J Hematol; 1990 Nov; 35(3):203-7. PubMed ID: 2220765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical use of factor IX concentrates].
    Nyman D
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DIC and postoperative wound bleeding under factor IX. Substitution therapy in a case of hemophilia B; sucessful treatment with heparin.
    Schimpf K; Zimmermann K; Kömpf B
    Thromb Res; 1976 Jan; 8(1):65-70. PubMed ID: 1251344
    [No Abstract]   [Full Text] [Related]  

  • 8. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
    Ohga S; Saito M; Matsukazi A; Kai T; Ueda K
    Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
    Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract]   [Full Text] [Related]  

  • 10. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
    Köhler M; Hellstern P; Lechler E; Uberfuhr P; Müller-Berghaus G
    Thromb Haemost; 1998 Sep; 80(3):399-402. PubMed ID: 9759617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 12. Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.
    Rodeghiero F; Castronovo S; Dini E
    Thromb Haemost; 1982 Dec; 48(3):339-40. PubMed ID: 6984544
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency.
    Manco-Johnson MJ; Bomgaars L; Palascak J; Shapiro A; Geil J; Fritsch S; Pavlova BG; Gelmont D
    Thromb Haemost; 2016 Jul; 116(1):58-68. PubMed ID: 27052576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A five year experience of the use of factor IX type DE(I) concentrate for the treatment of Christmas disease of Oxford.
    Lane JL; Rizza CR; Snape TJ
    Br J Haematol; 1975 Aug; 30(4):435-46. PubMed ID: 1201227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M; Toh CH; Thachil J; Watson HG
    Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disseminated intravascular coagulation(DIC)].
    Udvardy M
    Orv Hetil; 2001 Oct; 142(41):2243-50. PubMed ID: 11760467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group.
    Warrier I; Kasper CK; White GC; Shapiro AD; Bergman GE
    Am J Hematol; 1995 May; 49(1):92-4. PubMed ID: 7741147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On the causes of intra- and post-operative consumption coagulopathies and postoperative thromboembolism].
    Frick G; Frick U; Borchert K; Lange G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(4):575-82. PubMed ID: 72715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.